98 related articles for article (PubMed ID: 19174575)
1. BRCA1/2-associated and sporadic breast cancers: fellow travelers or not?
Garber JE
Cancer Prev Res (Phila); 2009 Feb; 2(2):100-3. PubMed ID: 19174575
[No Abstract] [Full Text] [Related]
2. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
3. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
4. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.
Garber JE; Golshan M
J Clin Oncol; 2009 Dec; 27(35):5862-4. PubMed ID: 19858367
[No Abstract] [Full Text] [Related]
5. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Evans DG; Howell A
Breast Cancer Res; 2004; 6(1):E7. PubMed ID: 14680492
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
8. [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].
Zhang HT; Lu YF; Zeng J; Lin J; Liao QH; Wan FQ
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):480-2. PubMed ID: 17686308
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Hudelist G; Wagner T; Rosner M; Fink-Retter A; Gschwantler-Kaulich D; Czerwenka K; Kroiss R; Tea M; Pischinger K; Köstler WJ; Attems J; Mueller R; Blaukopf C; Kubista E; Hengstschläger M; Singer CF
Endocr Relat Cancer; 2007 Dec; 14(4):1053-62. PubMed ID: 18045956
[TBL] [Abstract][Full Text] [Related]
10. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
11. Comments on: Sluiter MD and van Rensburg EJ, Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation.
del Valle J; Feliubadaló L; Lázaro C
Breast Cancer Res Treat; 2010 Nov; 124(1):295-6. PubMed ID: 20706784
[No Abstract] [Full Text] [Related]
12. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
13. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
14. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
15. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
16. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
17. Treating the genetic make-up of breast cancer: a new fashion?
Linn SC; Jonkers J
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
[No Abstract] [Full Text] [Related]
18. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
19. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
20. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
